The objective of this study was to perform antiphospholipid antibody screening in
women with chronic hypertension to assess whether the presence of such antibodies
is associated with adverse pregnancy outcome. Serum for anticardiolipin antibodies
and lupus anticoagulant was obtained in pregnant women with chronic hypertension who
had no other indications for such testing. The primary outcomes of interest were the
development of superimposed preeclampsia, preterm delivery, and fetal growth restriction.
Only 8 (9%) of the 87 women enrolled tested positive (> 95th percentile) for anticardiolipin
immunoglobulin G. None tested positive for lupus anticoagulant. The presence of antiphospholipid
antibodies was not associated with adverse pregnancy outcome. We were unable to demonstrate
that screening for antiphospholipid antibodies is a useful clinical practice in women
whose only pregnancy complication was chronic hypertension. The significance of such
antibodies in this particular group of patients can only be resolved with a large
multicenter study.
KEYWORDS
Antiphospholipid antibody - chronic hypertension - preeclampsia
REFERENCES
- 1
Branch D W, Scott J R, Kochenour N K, Hershgold E.
Obstetric complications associated with the lupus anticoagulant.
N Engl J Med.
1985;
313
1322-1326
- 2
Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R.
Outcome of treated pregnancies in women with antiphospholipid syndrome: an update
of the Utah experience.
Obstet Gynecol.
1992;
80
614-620
- 3
Lockwood C J, Romero R, Feinberg R F, Clyne L P, Coster B, Hobbins J C.
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin
antibodies in a general obstetric population.
Am J Obstet Gynecol.
1989;
161
369-373
- 4
Lima F, Khamashta M A, Buchanan N M, Kerslake S, Hunt B J, Hughes G R.
A study of sixty pregnancies in patients with the antiphospholipid syndrome.
Clin Exp Rheumatol.
1996;
14
131-136
- 5 Antiphospholipid syndrome .ACOG Educational Bulletin no. 244. Washington, DC; ACOG
February 1998
- 6
Levine J S, Branch D W, Rauch J.
The antiphospholipid syndrome.
N Engl J Med.
2002;
346
752-763
- 7
Branch D W, Porter T F, Rittenhouse L et al..
Antiphospholipid antibodies in women at risk for preeclampsia.
Am J Obstet Gynecol.
2001;
184
825-832
- 8
Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J.
Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid
syndrome? A randomized controlled trial.
Am J Obstet Gynecol.
2000;
183
1008-1012
- 9
Rai R, Cohen H, Dave M, Refan L.
Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women
with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid
antibodies).
BMJ.
1997;
314
253-257
- 10
Harris E N.
The second international anticardiolipin standardization workshop: the Kingston antiphospholipid
antibody study (KAPS) group.
Am J Clin Pathol.
1990;
94
476-484
- 11
Parry S, Macones G A, Roth N W, Desperito T J, Marzullo A, Morgan M A.
Antiphospholipid antibodies in chronic hypertension: the value of screening during
pregnancy.
Am J Perinatol.
1998;
15
527-531
Gerda G ZeemanM.D.
Department of Obstetrics and Gynecology, Academic Hospital Groningen, Hanzeplein 1
Postbus 30001, 9700 RB Groningen
The Netherlands